January 11, 2022 7:50am

A very weak aftermarket doesn’t say much for Tuesday

Pre-open indications: 6 BUYs and 1 SELL

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.19% (+71 points), S&P futures are UP +0.32% (+15 points) and NASDAQ futures are UP +0.47% (+74 points)

 

U.S. stocks were moving up in Tuesday pre-market after Nasdaq snap a four-day losing streak,

European stocks climbed as investors look ahead to tomorrow’s U.S. inflation reading,

Asia-Pacific markets were mixed as investors remain concerned about inflation, as well as likely policy tightening from central banks like the U.S. Fed.

 

Economic Data Docket: Fed Chair Powell’s confirmation hearing will take place

 

Henry’omics:

From the title meaning, “Things that are few and far between are very rare or do not happen very often.”

The Dow declined 0.45%, the S&P 500 dropped 0.1%, while the Nasdaq reversed slightly higher +6.93 points or +0.05%) after recovering from huge losses.

The stock market posted some positive action Monday, as the Nasdaq snapped a four-day losing streak and found support at its long-term 200-day line. The S&P 500 dropped for a sixth straight session, and gave up its key 50-day support level. <IBD>

 

If you didn’t remember what happen Monday night and the last session of 2021’s close, you won’t be prepared for today’s session:

RegMed Investors’ (RMi) closing bell: “RegMed Investors’ (RMi) closing bell: I’m not too early for the oversold party as I had written “it’s time to take a few risks. Well, I was right in some sense as more sector equities moved beyond 52-week lows along with the IBB and XBI” … https://www.regmedinvestors.com/articles/12250

Ebb and flow:

  • January to date, 1 neutral, 4 negative and 1 positive close

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Probabilities versus aftermarket/pre-open share pricing indication moves:

BUY:

Cellectis SA (CLLS) closed up +$0.20 to $7.92 after Friday’s -$0.20 to $7.72 with a positive +$0.83 or +10.48% pre-open indication as its licensed partner, Allogene Therapeutics, Inc. (ALLO) announced that the FDA had lifted the hold on its clinical trials. The FDA had placed a clinical hold on all five of ALLO’s clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogene’s ALPHA2 study. The investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene’s manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T™ product or in any other patient treated with the same ALLO-501A lot.

CRISPR Therapeutics (CRSP) closed up +$1.43 to $69.09 after Friday’s +$0.48 to $67.66 and Thursday’s -$1.83 to $67.18 with a positive +$0.61 or +0.88% pre-open indication,

Editas Medicine (EDIT) closed up +$0.56 to $25.70 after Friday’s +$0.73 to $25.14, Thursday’s -$0.19 to $24.41, Wednesday’s -$1.80 or -6.82% to $24.60 and last Tuesday’s -$1.23 to $26.40 with a positive +$0.30 or +1.17% pre-open indication

Global Blood Therapeutics (GBT) closed up +$0.54 to $29.17 after Friday’s +$0.22 to $28.63, Thursday’s +$0.74 to $28.41, Wednesday’s -$1.66 or -5.66% to $27.67 and last Tuesday’s $29.33 with a positive +$0.33 or +1.13% pre-open indication,

Ionis Pharmaceuticals (IONS) closed up +$0.13 to $30.51 with a positive +0.29 or +0.95% pre-open indication.

Vericel (VCEL) closed up +$2.46 to $38.94 after Friday’s -$1.96 to $36.448, Thursday’s $38.44, Wednesday’s $38.44 and last Tuesday’s $40.38 with a positive +$0.09 or +0.23% preopen indication.

 

Maintaining SELL:

Biostage (OTCQB: BSTG) closed down -$0.03 to $2.33 with 2,076 shares traded after Friday’s +$0.03 to $2.36 with 300 shares traded, Thursday’s flat with 1,165 shares traded, Wednesday’s +$0.01 with 262 shares traded and last Tuesday’s +$0.02 with 1626 shares traded. Will the “pump and promote” i.e., stimulate BUYING volume? Notice how the shares traded with and without the manipulated share pricing by volume stimulation; just a “House of Cards”?

 

 

The BOTTOM LINE: The sector remained under pressure but, did appreciate from the lows to close neutral i.e., gainers equaled losers.

Hopefully the pullback has been stymied with Monday’s close yet, the 52-week list of lows was “less” formidable than last weeks.

52-week Lows:

  • Applied Genetic Technologies (AGTC) hit a 52-week low of $1.73
  • Verastem (VSTM) hit a 52-week low of $1.83
  • Solid Biosciences (SLDB) hit a 52-week low of $1.53
  • Adverum Biosciences (ADVM) hit a 52-week low of $1.64
  • uniQure NV (QURE) hit a 52-week low of $18.71
  • CRISPR Therapeutics (CRSP) hit a 52-week low of $65.21
  • Homology Medicine (FIXX) hit a 52-week low of $3.44
  • Precigen (PGEN) hit a 52-week low of $3.11
  • Ultragenyx (RARE) hit a 52-week low of $71.86

The first morning of the J.P. Morgan Healthcare Conference is often a stage to unveil news … there was more than a bit of cell and gene therapy sector news that was announced with the start of the conference. <see in https://www.regmedinvestors.com/articles/12250  >

The “BUY” zone is still questionable but, there’s room for oversold movement, I am NOT changing my position, “Brace for more choppiness heading into the start of the year.”

  • I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.

  • RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.